

# Prognostic value of miR-17-5p in cancers: a meta-analysis

Weihao Kong\*  
Yusheng Cheng\*  
Hao Liang\*  
Qiangxing Chen  
Cuicui Xiao  
Kun Li  
Zenan Huang  
Jian Zhang

Department of Liver Transplantation,  
The Third Affiliated Hospital of Sun  
Yat-sen University, Guangzhou, China

\*These authors contributed equally  
to this work

**Background:** Studies have shown that miR-17-5p plays an important role in the development of cancer. The aim of this meta-analysis was to quantitatively analyze the association of miR-17-5p with prognosis in various cancers.

**Materials and methods:** We searched the PubMed, EMBASE, Web of Science, and Cochrane library databases for relevant studies through August 2017. The prognostic data and clinicopathological features of overall survival (OS) and disease-free survival (DFS) were extracted to investigate the association between miR-17-5p expression and tumor prognosis. In addition, odds ratios (ORs) were used to assess the correlations between miR-17-5p expression and clinicopathological characteristics.

**Results:** A total of ten studies were incorporated into this systematic review, and we found that high miR-17-5p expression can predict poor OS for malignancies (combined hazard ratio [HR]=1.87; 95% confidence interval [CI], 1.37–2.55;  $P=0.000$ ) as well as poor DFS (combined HR=1.60; 95% CI, 1.05–2.44;  $P=0.027$ ). Further subgroup analyses suggested that high miR-17-5p expression was related to poor OS in Asian patients (combined HR=1.92; 95% CI, 1.37–2.71;  $P=0.000$ ) and the serum/plasma sample source subgroup (combined HR=2.13; 95% CI, 1.36–3.31;  $P=0.001$ ). The combined OR indicated that the expression of miR-17-5p was associated with lymph node invasion (OR=1.28; 95% CI, 1.05–1.56;  $P=0.016$ ) and venous invasion (OR=1.92; 95% CI, 1.40–2.63;  $P=0.000$ ).

**Conclusion:** Elevated expression of miR-17-5p suggested a poor prognosis in cancer patients and may serve as a new tumor marker to monitor cancer development and progression.

**Keywords:** miR-17-5p, cancer, prognosis, meta-analysis

## Introduction

Cancer has become a global public health problem, seriously endangering human life in recent decades.<sup>1</sup> Early diagnosis of cancer greatly improves the survival of patients and their quality of life; however, there is no effective way to assess the prognosis of cancer patients based on clinical parameters. microRNAs (miRNAs), as a new type of biomarker, have gradually attracted the attention of many researchers.<sup>2</sup> miRNAs are non-coding RNAs of approximately 18–25 nucleotides that facilitate messenger RNA (mRNA) degradation and inhibit translation by binding to the 3'-untranslated region of the mRNA.<sup>3</sup>

Recently, a growing amount of evidence has shown that miRNAs are engaged in diverse biological processes, including cellular growth, differentiation, proliferation, metastasis, invasion, migration, and apoptosis.<sup>4–8</sup>

The miR-17-92 cluster (which is situated at the human 13q31 and includes miR-17-3p, miR-17-5p, miR-19a, miR-18a, miR-19b, miR-20a, and miR-92-1) first attracted the attention of researchers after a series of reports linked these miRNAs to

Correspondence: Jian Zhang  
Department of Liver Transplantation,  
The Third Affiliated Hospital of Sun  
Yat-sen University, 600 Tianhe Road,  
Guangzhou 510630, China  
Tel +86 137 6338 4046  
Email ml13763384046@163.com

tumor formation and progression.<sup>9</sup> Specifically, researchers have found that miR-17-5p is a crucial member of the miR-17 cluster family that is highly expressed in various cancers such as hepatocellular carcinoma (HCC),<sup>10,11</sup> lung cancer (LC),<sup>12</sup> colorectal cancer (CRC),<sup>13</sup> and other cancers.<sup>13–18</sup>

Furthermore, researchers have found that high expression of miR-17-5p is negatively correlated with overall survival (OS) and disease-free survival (DFS) in different kinds of cancers.<sup>10,11,19</sup> However, some studies have reported contradictory results; for example, Liu et al<sup>20</sup> observed that high expression of miR-17-5p could negatively regulate the invasion and migration of HCC cell lines. Until now, a systematic review of the prognostic value of miR-17-5p in human tumors has not been reported. Therefore, we performed this meta-analysis to explore the prognostic role of elevated miR-17-5p expression in various cancers.

## Materials and methods

### Literature search

To identify relevant studies, we searched the online PubMed, EMBASE, Web of Science, and the Cochrane library database through July 2017. The keywords for the search were as follows: “miR-17-5p”, “microRNA-17-5p”, “miRNA-17-5p”, “cancer”, “carcinoma”, “neoplasm”, and “tumor” in combination with “prognosis”. In addition, the references of identified articles were also explored for additional relevant articles. All of the articles were reviewed by three investigators independently, and any disagreements were settled by discussion.

### Inclusion and exclusion criteria

Researchers first screened the title and abstract and then screened out articles by skimming the full text. An eligible study was selected if it was consistent with the following inclusion criteria: 1) the study was based on human research; 2) hazard ratios (HRs) and their 95% confidence intervals (CIs) could be extracted from the article; 3) all patients could be separated into high and low expression level groups based on miR-17-5p quantity; and 4) the study was written in English and its full text was available.

Exclusion criteria for the articles were as follows: 1) the study was conducted using animals and/or cell lines; 2) the study was a systematic review or case report; 3) the study was not written in English; 4) the study lacked significant data; and 5) the study was a repeat study.

### Data extraction

Three investigators (Kong WH, Cheng YS, and Liang H) extracted the data and information from the selected studies.

Any disagreements were resolved through a panel discussion. Extracted data from the eligible studies included cancer type, the first author's surname, country, sample size, specimen source, test method, criteria for high miR-17-5p expression, rate of high miR-17-5p expression, follow-up period, age, gender, tumor depth, lymph node invasion, metastasis, vein invasion, histology differentiation, tumor size, and HRs with corresponding 95% CIs for OS, progress-free survival (PFS), and DFS.

### Quality evaluation

We assessed the selected studies using the MOOSE method proposed by the Netherland Cochrane Center. The basic principles of this analysis included determining if 1) the number of patients was sufficient; 2) the design method was clear; 3) sufficient data were reported; 4) the results were clearly evaluated; 5) miR-17-5p measurement was described in detail; and 6) adequate follow-up time was available for each study.<sup>21</sup> Studies that did not meet the above six requirements were excluded.

### Statistical analysis


Statistical analyses of the HRs for OS, DFS, and odds ratios (ORs) for clinicopathological characteristics were computed using STATA and RevMan software. Heterogeneity was assessed using  $Q$  tests and  $I^2$  statistics ( $P < 0.05$  or  $I^2 > 50%$  was deemed to be statistically heterogeneous). When the heterogeneity of the combined study was small ( $I^2 < 50%$ ,  $P < 0.10$ ), we used the fixed effect model for statistical analysis. Otherwise, a random effects model was used. Subgroup analysis was conducted to further explore the association of miR-17-5p with sample size, ethnicity, source, definition method, tumor type, and statistical mode for various carcinomas. We used Egger's test, Begg's test, and funnel plots to detect publication bias. Sensitive analysis was also implemented to evaluate the stabilization of the results. A  $P$ -value below 0.05 was deemed to be statistically significant.

## Results

### Literature search and study characteristics

According to the inclusion and exclusion criteria, we selected a total of ten articles with data from approximately 1,135 people for meta-analysis, and the detailed selection steps are shown in Figure 1.

We summarize the major features of the selected studies in Table 1. Among these ten studies, nine measured miR-17-5p expression using polymerase chain reaction (PCR), while one study performed PCR and in situ hybridization (ISH).



**Figure 1** Study flow chart showing the process for selecting eligible publications.

Across these the ten studies, patients were diagnosed with CRC HCC, colon cancer (CC), gastric cancer (GC), childhood infratentorial ependymoma (CIE), pancreatic cancer (PC), osteosarcoma (OSA), nasopharyngeal carcinoma (NPC), and LC. Eight studies directly provided HRs and 95% CIs, one study provided only a survival curve, and one study provided only the risk ratios (RRs); thus, we merged RRs and HRs.

### miR-17-5p expression and OS

We included ten studies of OS in our analysis. Considering that potential heterogeneity may have been introduced in this study, we used a random effect model to conservatively estimate the effect of combined HRs and 95% CIs. We found that patients with high expression of miR-17-5p had a worse prognosis than those with low expression of miR-17-5p (HR=1.87; 95% CI, 1.37–2.55;  $P=0.000$ ) (Figure 2).

To lessen the impact of heterogeneity, subgroup analyses were performed for sample size, ethnicity, sources of detected sample source, definition method, tumor types, and statistical mode (Table 2). First, we found that the expression level of miR-17-5p had a statistically significant effect on OS in subgroups with a sample size greater than or equal to 100 (HR=2.15; 95% CI, 1.37–3.37;  $P=0.001$ ) as well as subgroups with a sample size of less than 100 (HR=1.72;

95% CI, 1.11–2.68;  $P=0.016$ ). Second, we observed that miR-17-5p had a statistically significant effect on OS in the Asians patient subgroup (HR=1.92; 95% CI, 1.37–2.71;  $P=0.000$ ), but no statistical significance was found in the European patient subgroup. Third, when we conducted a subgroup analysis for the sample source, we found that miR-17-5p was more strongly associated with the plasma/serum subgroup (HR=2.13; 95% CI, 1.36–3.31;  $P=0.001$ ) than the tissue subgroup (HR=1.69; 95% CI, 1.05–2.71;  $P=0.031$ ) using a random effects model. Fourth, miR-17-5p has a stronger correlation with median definition than other definition methods (HR=2.08; 95% CI, 1.54–2.81;  $P=0.000$ ). Fifth, in a subgroup analysis stratified by the cancer type, all three of the subgroups showed a strong correlation between miR-17-5p and OS with a random effects model, indicating that miR-17-5p has a predictive effect for different kinds of tumors. Finally, considering that the combination of univariate analysis and multivariate analysis is unreasonable, we performed a subgroup analysis for statistical mode, and the results were consistent with the overall combined effect. Therefore, the conclusion is stable and credible.

### miR-17-5p expression and DFS

Two studies focused on DFS analysis. Heterogeneity results showed a small amount of heterogeneity ( $I^2=0$ ;  $P=0.360$ ), so we use a fixed effect model to compute the

Table 1 Characteristics of the included studies

Tumor type	Reference	Region	Sample size	Specimen source	Test method	Definition of high miR-17-5p expression	Rate of high miR-17-5p expression	Tumor stage	Follow-up time (months)	Survival	HR
HCC	Chen et al <sup>10</sup>	China	120	Tissue	PCR	Median	56.7	Edmondson–Steiner grade (I–IV)	2–46	OS <sup>MA</sup> DFS <sup>MA</sup>	RR
CIE	Zakrzewska et al <sup>15</sup>	Poland	53	Tissue	PCR	Median	NR	WHO (I–III)	Up to 120	OS <sup>MA</sup> EFS <sup>MA</sup>	R
GC	Wang et al <sup>17</sup>	China	65	Plasma	PCR	Median	50.8	TNM (I–IV)	Up to 40	OS <sup>UA</sup>	R
CC	Diaz et al <sup>18</sup>	Spain	62	Tissue	PCR	Tertile	33.9	TNM (I–IV)	68–99	OS <sup>UA</sup> DFS <sup>UA</sup>	R
HCC	Zheng et al <sup>11</sup>	China	96	Serum	PCR	Median (2.705)	50	TNM (I–IV)	From resection to death or May 1, 2012	OS <sup>MA</sup>	R
PC	Yu et al <sup>19</sup>	Japan	80	Tissue	PCR	Cutoff value (5.69)	37.5	UICC (I–IV)	Up to 100	OS <sup>MA</sup>	R
CRC	Fang et al <sup>13</sup>	China	295	Tissue	PCR ISH	Staining score (8–12)	30.2	TNM (I–IV)	Up to 96	OS <sup>MA</sup>	R
NPC	Chen et al <sup>16</sup>	China	81	Tissue	PCR	Staining score (tai)	75.3	TNM (I–IV)	Up to 100	OS <sup>UA</sup>	SC
LC	Chen et al <sup>12</sup>	China	221	Serum	PCR	Median (33 months)	45.7	TNM (I–IV)	Up to 50	OS <sup>UA</sup>	R
OSA	Zhu et al <sup>14</sup>	China	62	Plasma	PCR	Mean	NR	TNM (I–III)	10–70 (OS) 10–60 (PFS)	OS <sup>MA</sup> PFS <sup>MA</sup>	R

**Abbreviations:** HR, hazard ratio; HCC, hepatocellular carcinoma; CIE, childhood infratentorial ependymoma; GC, gastric cancer; CC, colon cancer; PC, pancreatic cancer; NPC, nasopharyngeal carcinoma; LC, lung cancer; OSA, osteosarcoma; PCR, polymerase chain reaction; ISH, in situ hybridization; NR, not reported; WHO, World Health Organization; TNM, tumour node metastases; UICC, Union for International Cancer Control; OS, overall survival; PFS, progress-free survival; DFS, disease-free survival; MA, multivariate analysis; UA, univariate analysis; RR, risk ratio; R, reported; SC, survival curve.

combined HRs and 95% CIs for DFS. The results showed that the DFS of patients with elevated miR-17-5p expression was more affected than that of patients with decreased miR-17-5p expression (HR=1.60; 95% CI, 1.05–2.44; *P*=0.027) (Figure 3). Because only two studies reported DFS, the data are too limited to perform subgroup analysis for DFS.

### miR-17-5p expression and clinicopathological characteristics

Meta-analysis indicated that elevated miR-17-5p expression was associated with lymph node invasion (OR=1.28; 95% CI, 1.05–1.56; *P*=0.016) and venous invasion (OR=1.92; 95% CI, 1.40–2.63; *P*=0.000) (Table 3). No significant correlations were found for age (*P*=0.24), gender (*P*=0.212), tumor invasion depth (*P*=0.400), distant metastasis (*P*=0.499), tumor stage (*P*=0.804), differentiation grade (*P*=0.077), tumor size (*P*=0.291), or hepatitis history (*P*=0.550). Due to insufficient data, we failed to detect any correlations between elevated miR-17-5p expression and other clinicopathological characteristics.

### Sensitivity analysis


Sensitivity analysis was implemented to assess the influence of each individual study on the integrated results of OS. We excluded each study, re-merged the meta-analysis results and then compared the results of the unexcluded meta-analysis to investigate the stability of the results. This analysis showed that the combined HR for the effect of miR-17-5p expression on OS was not remarkably influenced after eliminating any of the individual studies (Figure 4).

### Publication bias

We use Egger’s tests and funnel plots to detect the publication bias. The results of the funnel plot for OS are shown in Figure 5. Since the Egger’s test has a *P*-value greater than 0.05, no publication bias was found. Due to the small number of studies that reported DFS, we were not able to determine the publication bias for DFS.

### Discussion

In recent years, miRNAs have been considered to be closely related to carcinogenic processes such as angiogenesis, proliferation, differentiation, invasion, apoptosis, and metastasis.<sup>9</sup> It is presumed that more than one third of human genes are regulated by miRNAs,<sup>22</sup> which serve as negative regulatory molecules of gene expression at the posttranscriptional translation phase and are widely involved in the development



**Figure 2** Forest plot of the overall survival analysis.

**Note:** Weights are from random-effects analysis.

**Abbreviations:** CI, confidence interval; ES, effect size.

and progression of human diseases, particularly human cancer.<sup>23</sup> Since the publication of reviews about miRNA-17-5p in multiple journals, miR-17-5p has gradually attracted the attention of many researchers as a molecule of interest.


miR-17-5p has also been found to be closely associated with the development of tumors.<sup>9,24–26</sup> However, as no quantitative systematic reviews about miR-17-5p have been published so far, we conducted this meta-analysis.

**Table 2** The pooled HRs, 95% CIs, heterogeneity, and *P*-values of overall survival stratified by sample size, ethnicity, sample sources, definition method, tumor type, and statistical mode

Stratified analysis	Number of studies	Number of patients	Pooled HR (95% CI)	<i>P</i> -value	Heterogeneity			Test of interaction <i>P</i> -value
					<i>I</i> <sup>2</sup> (%)	<i>P</i> -value	Model	
Sample size								
≥ 100	3	636	<b>2.15 (1.37–3.37)</b>	0.001	38.6	0.196	Random	0.49
< 100	7	499	<b>1.72 (1.11–2.68)</b>	0.016	48.6	0.070	Random	
Dominant ethnicity								0.82
Asian	8	1,020	<b>1.92 (1.37–2.71)</b>	0.000	47.2	0.066	Random	0.48
European	2	115	1.69 (0.57–5.00)	0.344	55.6	0.133	Random	
Source								0.80
Tissue	6	691	<b>1.69 (1.05–2.71)</b>	0.031	50.7	0.071	Random	0.15
Serum/plasma	4	444	<b>2.13 (1.36–3.31)</b>	0.001	40.5	0.169	Random	
Definition								0.19
Median	5	555	<b>2.08 (1.54–2.81)</b>	0.000	1.5	0.398	Random	0.15
Stain score	2	376	1.77 (0.57–5.50)	0.327	76.4	0.015	Random	
Others	3	204	<b>1.76 (1.15–2.67)</b>	0.008	0	0.438	Random	
Tumor types								0.19
Digestive system	6	718	<b>1.73 (1.20–2.49)</b>	0.003	45.2	0.104	Random	0.19
Respiratory system	2	302	<b>1.63 (1.02–2.60)</b>	0.040	0	0.531	Random	
Others	2	115	<b>5.33 (1.72–16.50)</b>	0.004	27.3	0.241	Random	
Statistical mode								
Univariate analysis	4	429	<b>1.59 (1.17–2.17)</b>	0.003	0	0.663	Random	0.19
Multivariate analysis	6	706	<b>2.43 (1.39–4.26)</b>	0.002	61.4	0.024	Random	

**Note:** Data in bold *P*<0.05.

**Abbreviations:** CI, confidence interval; HR, hazard ratio.



**Figure 3** Forest plot of disease free survival analysis.  
**Abbreviations:** CI, confidence interval; ES, effect size.

In this study, we strictly adhered to the MOOSE guidelines to perform the meta-analysis and to assess the quality of the included studies using the scales recommended by the Cochrane Collaboration.<sup>21</sup> The results indicated that high expression of miR-17-5p plays an unfavorable role in OS and DFS. Considering the potential heterogeneity of the included studies, we used a random effects model to combine the data and then performed subgroup analysis, sensitivity analysis, and publication bias detection; the findings of these analyses show that our results are stable and credible.

Furthermore, we carried out subgroup analyses to explore the prognostic significance of miR-17-5p in OS, and we have successfully drawn some valuable conclusions for clinical practice. To rule out the impact of different races on prognosis, we divided the ten studies into patient groups of Asian and European ethnicities. We observed that the elevated expression of miR-17-5p predicts significantly worse OS in Asian


patients (pooled HR=1.92; 95% CI, 1.37–2.71;  $P=0.000$ ), but no statistical significance was found in European patients (combined HR=1.69; 95% CI, 0.57–5.00,  $P=0.344$ ) (Table 2). This difference may be due to the different genetic backgrounds, geographical locations, climates etc., of the different races. Therefore, we concluded that miR-17-5p might be a more valuable predictor of cancer prognosis in Asian populations. To illustrate the relationship between the expression level of miR-17-5p and prognosis using different sample sources, we divided the patients into two subgroups, serum/plasma and tissue, and we observed that the serum/plasma group had a worse prognosis (combined HR=2.13; 95% CI, 1.36–3.31;  $P=0.001$ ) than tissue-derived specimens (combined HR=1.69; 95% CI, 1.05–2.71;  $P=0.031$ ) (Table 2). Although the detection of miR-17-5p in tumor specimens has been widely used to study tumor prognosis, plasma/serum specimen detection is more convenient and effective, and it

**Table 3** Meta-analysis results of the correlation between elevated miR-17-5p expression and multiple clinicopathological characteristics

Stratified analysis	Number of studies	Number of patients	Pooled OR (95% CI)	P-value	Heterogeneity		
					$I^2$ (%)	P-value	Model
Age (old vs young)	6	663	1.08 (0.95–1.24)	0.240	0	0.578	Fixed
Gender (male vs female)	6	663	0.92 (0.80–1.05)	0.212	0	0.809	Fixed
Invasion depth (T3+T4 vs T1+T2)*	2	160	1.45 (0.61–3.45)	0.400	87.7	0.004	Random
Lymph node invasion ( $\geq 2$ vs $< 2$ )	2	201	<b>1.28 (1.05–1.56)</b>	0.016	0	0.404	Fixed
Distant metastasis (yes vs no)	3	242	1.24 (0.66–2.32)	0.499	83.4	0.002	Random
Tumor stage (III+IV vs I+II)	4	463	1.09 (0.56–2.10)	0.804	88.8	0.000	Random
Venous invasion (yes vs no)	2	200	<b>1.92 (1.40–2.63)</b>	0.000	0	0.776	Fixed
Differentiation grade (poorly vs well and moderately)	2	161	1.33 (0.97–1.84)	0.077	0	0.361	Fixed
Tumor size ( $> 5$ vs $< 5$ ) (cm)	3	281	0.90 (0.62–1.30)	0.291	53.4	0.117	Random
Hepatitis history (yes vs no)	3	216	1.20 (0.66–2.16)	0.550	58.9	0.119	Random

**Notes:** \*According to the size of the tumor and/or the extent of the primary tumor are defined as different T stages. Data in bold  $P < 0.05$ .

**Abbreviations:** CI, confidence interval; OR, odds ratio.




**Figure 4** Sensitivity analysis of overall survival in this meta-analysis.

can efficiently assess the risk of hospital stay and postoperative recurrence. The expression of miR-17-5p in the blood is more predictive than in tissue, which can be applied in clinical research. Therefore, the detection of miR-17-5p in plasma/serum during postoperative follow-up periods might be an effective way to closely monitor disease-progression and treatment in cancer patients.

Moreover, we carried out meta-analyses with respect to pathological characteristics. We found that elevated miR-17-5p expression is predominantly correlated with

lymph node invasion (combined OR=1.28; 95% CI, 1.05–1.56;  $P=0.016$ ) and venous invasion (combined OR=1.92; 95% CI, 1.40–2.63;  $P=0.000$ ). No statistically significant correlations were found for age, gender, tumor invasion depth, distant metastasis, tumor stage, differentiation grade, or hepatitis history. Therefore, we concluded that miR-17-5p may be involved in the progression of lymphatic metastasis and vein invasion in cancer.

To the best of our knowledge, miR-17-5p has been found to be closely associated with cancers through complicated regulatory mechanisms.<sup>9</sup> For instance, Yang et al<sup>27</sup> observed that miR-17-5p can facilitate the migration and proliferation of human liver cancer cells through the p38-MAPK-HSP27 pathway. Li et al<sup>28</sup> discovered that miR-17-5p can boost the invasion and migration of human breast tumor cells by inhibiting HMG box-containing protein 1 (HBP1), a tumor suppressor. Qu et al<sup>29</sup> observed that miR-17-5p can negatively regulate transforming growth factor-beta receptor 2 (TGFBR2), which serves as an original regulator of the TGF-beta signaling pathway, and reduction or loss of its expression can lead to uncontrolled cell proliferation and invasion, thus promoting cell growth and migration. Wang et al<sup>30</sup> noticed that miR-17-5p can promote the proliferation of OSA in a breast cancer cell 2 (BRCC2)-dependent mechanism, which plays a key role in suppressing tumorigenesis.



**Figure 5** Begg's funnel plot with pseudo 95% CI of the publication bias for overall survival.

**Abbreviations:** lnhr, logarithm of the hazard ratio; SE, standard error.

To some extent, these mechanisms explain why patients with elevated miR-17-5p expression have multiple lymphatic metastases and venous violations, but the specific mechanism still requires further investigation.

These studies had several limitations. First, the definition of high miR-17-5p expression was not the same across studies; thus, it was difficult to define miR-17-5p overexpression in various cancers. Second, the study included a total of only ten articles; therefore, the data are not sufficient. Third, there was considerable heterogeneity among the different studies in terms of cancer type, specimen source, detection method and definition of high miR-17-5p expression. Fourth, eligible studies only included positive results, and there may be publication bias. Fifth, combining univariate and multivariate analysis is somewhat unreasonable. Finally, part of the HR value was calculated using a survival curve, which may lead to some error.

## Conclusion and recommendations

Our meta-analysis has explored the predictive value of miR-17-5p in different types of carcinomas. miR-17-5p may serve as a new tumor marker for predicting prognosis and for evaluating the clinicopathological characteristics of different kinds of carcinomas. Ultimately, considering the limitations of this study, these conclusions require additional large-sample and high-quality research to further clarify the relationship between miRNA-17-5p and prognosis.

## Acknowledgment

The authors acknowledge their research group fund: Guangzhou Science and Technology Plan Project (201707010112).

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin*. 2017;67(1):7–30.
- Kleemann M, Bereuther J, Fischer S, et al. Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis. *Oncotarget*. 2017;8(12):18773–18791.
- Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. *Cancer Res*. 2016;76(13):3666–3670.
- Ahmadi S, Sharifi M, Salehi R. Locked nucleic acid inhibits miR-92a-3p in human colorectal cancer, induces apoptosis and inhibits cell proliferation. *Cancer Gen Ther*. 2016;23(7):199–205.
- Zhao X, He W, Li J, et al. MiRNA-125b inhibits proliferation and migration by targeting SphK1 in bladder cancer. *Am J Transl Res*. 2015;7(11):2346–2354.
- Zhang JX, Xu Y, Gao Y, et al. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. *Mol Cancer*. 2017;16(1):18.
- Zhang J, Sun Q, Zhang Z, Ge S, Han ZG, Chen WT. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. *Oncogene*. 2013;32(1):61–69.
- Liang B, Chen Y, Yuan W, et al. Down-regulation of miRNA-451a and miRNA-486-5p involved in benzene-induced inhibition on erythroid cell differentiation in vitro and in vivo. *Arch Toxicol*. 2018;92(1):252–272.
- Fuziwara CS, Kimura ET. Insights into regulation of the miR-17-92 cluster of miRNAs in cancer. *Front Med (Lausanne)*. 2015;2:64.
- Chen L, Jiang M, Yuan W, Tang H. miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. *J Invest Surg*. 2012;25(3):156–161.
- Zheng J, Dong P, Gao S, Wang N, Yu F. High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma. *HepatoGastroenterology*. 2013;60(123):549–552.
- Chen Q, Si Q, Xiao S, et al. Prognostic significance of serum miR-17-5p in lung cancer. *Med Oncol*. 2013;30(1):353.
- Fang L, Li H, Wang L, et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. *Oncotarget*. 2014;5(10):2974–2987.
- Zhu HX, Liao QD, Yin K, Da Zhong D, Wang CG. Circulating miR-17-5p as a potential biomarker for diagnosis and prognosis in osteosarcoma. *Int J Clin Exp Pathol*. 2017;10(3):3409–3416.
- Zakrzewska M, Fendler W, Zakrzewski K, et al. Altered microRNA expression is associated with tumor grade, molecular background and outcome in childhood infratentorial ependymoma. *PLoS One*. 2016;11(7):e0158464.
- Chen C, Lu Z, Yang J, et al. MiR-17-5p promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting p21. *Cancer Med*. 2016;5(12):3489–3499.
- Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. *Mol Med Rep*. 2012;5(6):1514–1520.
- Diaz R, Silva J, Garcia JM, et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. *Genes Chromosomes Cancer*. 2008;47(9):794–802.
- Yu J, Ohuchida K, Mizumoto K, Fujita H, Nakata K, Tanaka M. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. *Cancer Biol Ther*. 2010;10(8):748–757.
- Liu D, Dong L, Liu Y, et al. A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma. *Tumour Biol*. 2016;37(4):5039–5047.
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283(15):2008–2012.
- Lin SB, Gregory RI. MicroRNA biogenesis pathways in cancer. *Nature Rev Cancer*. 2015;15(6):321–333.
- Shen J, Hung MC. Signaling-mediated regulation of microRNA processing. *Cancer Res*. 2015;75(5):783–791.
- Dellago H, Bobbili MR, Grillari J. MicroRNA-17-5p: at the crossroads of cancer and aging – a mini-review. *Gerontology*. 2017;63(1):20–28.
- Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. *Cell*. 2008;132(5):875–886.
- Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. *Cell*. 2008;133(2):217–222.



27. Yang F, Yin Y, Wang F, et al. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. *Hepatology*. 2010;51(5):1614–1623.
28. Li H, Bian C, Liao L, Li J, Zhao RC. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. *Breast Cancer Res Treat*. 2011;126(3):565–575.
29. Qu Y, Zhang H, Duan J, et al. MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor- $\beta$  receptor 2 in gastric cancer. *Oncotarget*. 2016;7(22):33286–33296.
30. Wang W, Zhang L, Zheng K, Zhang X. miR-17-5p promotes the growth of osteosarcoma in a BRCC2-dependent mechanism. *Oncol Rep*. 2016;35(3):1473–1482.

### OncoTargets and Therapy

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress